Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249600 | 0.77 | KDM4E (0.39) | LMNAFDPSPDE3AADRB3PDE4D | |
| SCHEMBL3144201 | 0.69 | FDPS (0.48) | LMNAFDPSPDE3AADRB3PDE4D | |
| SCHEMBL8899019 | 0.69 | LMNA (0.38) | LMNAFDPSPDE3AADRB3PDE4D | |
| SCHEMBL19211976 | 0.68 | GGPS1 (0.43) | LMNAFDPS | |
| SCHEMBL10784249 | 0.65 | KDM4E (0.39) | LMNAFDPSPDE3AADRB3PDE4D | |
| SCHEMBL18149028 | 0.65 | LMNA (0.48) | LMNAFDPSPDE3AADRB3PDE4D | |
| SCHEMBL6659016 | 0.64 | KDM4E (0.44) | LMNAFDPSKDM4EMMP2THRB | |
| SCHEMBL3365741 | 0.63 | — | — | |
| SCHEMBL27469645 | 0.63 | LMNA (0.45) | LMNAFDPSKDM4EMMP2THRB | |
| SCHEMBL11746955 | 0.63 | FDPS (0.43) | LMNAFDPSPDE3AADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994013688-A1 | DNA-ARMED RIBOZYMES AND MINIZYMES | GENE SHEARS PTY. LIMITED (AU) | 1994-06-23 | — | — | WO | claimed |
| US-9868955-B2 | Human toll-like receptor inhibitors and methods of use thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2900823-B1 | HUMAN TOLL-LIKE RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | DYNAVAX TECH CORP (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2209896-B1 | METHODS AND COMPOSITIONS FOR INHIBITION OF IMMUNE RESPONSES AND AUTOIMMUNITY | DYNAVAX TECH CORP (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2361980-B1 | Methods and compositions for inhibition of immune responses and autoimmunity | DYNAVAX TECH CORP (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9476053-B2 | Methods and compositions for inhibition of immune responses and autoimmunity | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2016-10-25 | — | — | US | disclosed |
| US-9347064-B2 | Methods of treatment using TLR7 and/or TLR9 inhibitors | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2582398-B1 | METHODS OF TREATMENT USING TLR7 AND/OR TLR9 INHIBITORS | DYNAVAX TECH CORP (US) | 2016-04-13 | — | — | EP | disclosed |
| US-9228184-B2 | Human toll-like receptor inhibitors and methods of use thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150297737-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | DYNAVAX TECHNOLOGIES CORPORATION | 2015-10-22 | — | — | US | disclosed |
| US-20030199466-A1 | For modulating an immune response | DYNAVAX TECHNOLOGIES CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-20030175731-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | DYNAVAX TECHNOLOGIES CORPORATION | 2003-09-18 | — | — | US | disclosed |
| US-20030165969-A1 | Non-nucleotide containing enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6555668-B2 | Comprising a non-nucleotide in a single-stranded region; hammerhead ribozyme having a non-nucleotide in the catalytic core; synthesis of abasic ribonucleoside mimetics | RIBOZYME PHARMACEUTICALS, INC. | 2003-04-29 | — | — | US | disclosed |
| WO-2003000922-A2 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020193579-A1 | Non-nucleotide containing enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6362323-B1 | HAVING ACTIVITY TO CLEAVE AN RNA OR DNA MOLECULE | RIBOZYME PHARMACEUTICALS, INC. | 2002-03-26 | — | — | US | disclosed |
| US-6117657-A | ENZYMATIC NUCLEIC ACID MOLECULE CONTAINING ONE OR MORE NON-NUCLEOTIDE MIMETICS, AND HAVING ACTIVITY TO CLEAVE AN RNA OR DNA MOLECULE | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-5891683-A | Non-nucleotide containing enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1994013688-A1 | DNA-ARMED RIBOZYMES AND MINIZYMES | GENE SHEARS PTY. LIMITED (AU) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199466-A1 | For modulating an immune response | IFNG, ICOS, CD47 | LMNA 4839/4885FDPS 759/4885PDE3A 1217/4885 |
| US-20030175731-A1 | Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies | TSLP, CD74, MICA | LMNA 4831/4885FDPS 1322/4885PDE3A 1802/4885 |
| US-20150297737-A1 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV | ICOS, CD47, IL2 | LMNA 4667/4885FDPS 1119/4885PDE3A 2456/4885 |
| US-20030165969-A1 | Non-nucleotide containing enzymatic nucleic acid | RNGTT, RNASE1, NSUN2 | LMNA 755/4885FDPS 868/4885PDE3A 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.